Companies
Nestlé Purina PetCare
FortiFlora (E. faecium SF68) — Microencapsulated, >$300M in pet probiotic sales, most vet-recommended US brand.
- Country
- United States
NASC Quality Seal
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Nestlé planned $3 billion in global capital investment for PetCare between 2022 and 2025, with almost $2 billion invested in Purina in North America by the end of 2025. | nestle.com |
| Capacity | Purina has been expanding production capacity globally and in the U.S. to address constraints, including major expansions at facilities like Clinton, Iowa, and Hartwell, Georgia. | nestle.com · nestleusa.com · prnewswire.com |
| Certification | FortiFlora has earned the NASC Quality Seal; Purina's North American manufacturing locations have implemented ISO 14001 certified environmental management systems. | nestle.com · purina.com |
| Production site | Purina operates numerous U.S. factories, including the site in Clinton, Iowa, which produces FortiFlora, and the Hartwell, Georgia, facility. | filecache.mediaroom.com · nestleusa.com · prnewswire.com |
| Headcount | Purina employs more than 8,700 associates in the U.S. and over 25,000 associates globally for its PetCare business. | filecache.mediaroom.com · nestle.com · nestleusa.com · prnewswire.com · purina.com |
| Revenue | Nestlé PetCare global sales exceeded CHF 18 billion in 2022 and reached 18.9 billion CHF in 2023. | nestle.com · statista.com |
Independent sources: filecache.mediaroom.com · nestleusa.com · prnewswire.com · purina.com · statista.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Probiotics and postbiotics for companion animals | food-alt-protein | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.